CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Caribou Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.46−0.01 (-1.26%)
Close on Oct 19, 2026
- Market cap
- $46.86M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.1660 (−82.36%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Caribou Biosciences, Inc. grew revenue 10.0% to $10.04M over the twelve months to Jun 30, 2026. Free cash flow was -$95.75M.
Revenue
$10.04M
+10.0% vs. a year earlier
Operating income
-$109.47M
TTM Q2 2026
Free cash flow
-$95.75M
TTM Q2 2026
EPS, diluted
-$1.08
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $46.86M
- P/E ratio
- –
- Price to sales
- 4.67
- Price to book
- 0.48
- Dividend yield
- –
- Free cash flow yield
- -204.35%
Fundamentals
- Revenue
- $10.04M
- Net income
- -$103.40M
- EPS, diluted
- -$1.08
- Free cash flow
- -$95.75M
- Book value per share
- $0.97
- Diluted shares
- 101M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$10.04M+10.0% YoY
Operating income
-$109.47M
Net income
-$103.40M
EPS, diluted
-$1.08
Free cash flow
-$95.75M
Reported periodTrailing twelve months